HEARTFLOW INC (HTFL)

Sector: Health Care

    Home/Companies/HTFL/Annual Meeting

2026 Annual Meeting Analysis

HEARTFLOW INC · Meeting: June 16, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

2

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of the two nominees as Class I directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified

2 FOR
✓ FOR
Julie A. Cullivan

Ms. Cullivan has served since November 2020, passes the TSR trigger (HTFL's 3-year return of -3.0% trails XLV by only 14.8 percentage points, well below the 30-point threshold for negative absolute TSR), meets attendance requirements, has relevant technology and cybersecurity experience, and no overboarding, independence, or familial-relationship concerns are present.

✓ FOR
John C.M. Farquhar

Mr. Farquhar is the CEO and executive director; he has served since March 2022, the TSR trigger does not fire (gap of -14.8 percentage points versus XLV is below the 30-point threshold required for a negative-absolute-TSR company), attendance is satisfactory, and he brings directly relevant healthcare and medical-device executive experience with no overboarding or familial-relationship issues.

Both Class I nominees pass all policy screens: the stock performance trigger does not fire (HTFL's 3-year price return of -3.0% underperforms XLV by only 14.8 percentage points, below the 30-point threshold applicable to companies with negative absolute TSR), attendance was at or above 75% for all directors, no director is overboarded, audit committee members hold financial-expert designations, and no familial relationships with management exist.

Say on Pay

✓ FOR

CEO

John C.M. Farquhar

Total Comp

$5,989,882

Prior Support

N/A

This is Heartflow's first annual meeting as a public company (IPO completed August 2025), so there is no prior Say on Pay vote history and no prior-year support threshold to apply. The CEO's total reported compensation of approximately $6.0 million for 2025 is broadly in line with benchmarks for a CEO at a healthcare technology company with a $2.5 billion market cap; the majority of that pay consists of variable components (stock options, restricted stock units, and a performance-based cash bonus at 112.2% of target tied to disclosed corporate objectives including revenue, gross margin, product development, and quality). The company has adopted a Dodd-Frank-compliant clawback policy, and the compensation structure reflects a reasonable pay mix with performance-linked incentives that are appropriate for an emerging-growth-stage company.

Auditor Ratification

✓ FOR

Auditor

PricewaterhouseCoopers LLP

Tenure

16 yrs

Audit Fees

$2,895,000

Non-Audit Fees

$2,000

PwC's non-audit fees of $2,000 represent a negligible fraction of total audit fees of $2,895,000 (well under the 50% threshold), auditor tenure of approximately 16 years is below the 25-year trigger, PwC is a Big 4 firm appropriate for a $2.5 billion company, and no material financial restatements are disclosed.

Overall Assessment

The 2026 Heartflow annual meeting ballot contains two substantive proposals: election of two Class I directors and ratification of PwC as auditor. Both proposals pass all policy screens without exception — the TSR underperformance trigger does not fire for either director nominee, PwC's fee structure and tenure present no independence concerns, and the company's first-year executive compensation program reflects a reasonable performance-linked structure with a valid clawback policy.

Filing date: April 29, 2026·Policy v1.2·high confidence